People: Ablynx NV (ABLX.BR)
Dr. Edwin Moses, Ph.D., is Chairman of the Board of Directors, Chief Executive Officer and Member of the Executive Committee of Ablynx NV since June 6, 2006. He was first appointed to the Board as Independent Director on October 21, 2004. After he completed his post-doctoral research in Germany he started his career at Amersham International, Enzymatix and Raggio-Italgene. From 1993 until 2001 he worked at Oxford Asymmetry, first as Chief Executive Officer and later as Chairman until 2001. Dr. Moses has been Chairman of the Company since 2004, and in 2006 accepted the offer by the Company's Board to extend his role as Chairman to include that of Chief Executive Officer (CEO). Apart from and in addition to his duties as CEO and Chairman of the Company, Dr. Moses is Chairman of Lectus Therapeutics Ltd., Chairman of the Board of Capricorn Health-tech Fund (Belgium) and Member of the Board of Directors of the European Biopharmaceutical Enterprises. Furthermore, in the past five years, in addition to Ablynx, he has held Board memberships with the following companies: Clinphone Group plc, Fusion IP plc (formerly Biofusion plc), Phoqus Pharmaceuticals Ltd, Pharmaceutical Profiles Ltd, Proimmune Ltd, Paradigm Therapeutics Ltd, Avantium Technologies (the Netherlands), Ionix Pharmaceuticals Ltd, Evotec OAI AG, Bioimage A/S, Inpharmatica Ltd, Prolysis Ltd, ProPharma Ltd, Lectus Therapeutics Ltd. and the European Biopharmaceutical Enterprises.
|Total Annual Compensation, EUR||Long-Term Incentive Plans, EUR||All Other, EUR||Fiscal Year Total, EUR|